| 1 | cluster | 5,144 |
| 2 | batch | 482 |
| 3 | fed-batch | 110 |
| 4 | quasi | 109 |
| 5 | mendelian | 95 |
| 6 | coin | 88 |
| 7 | pedigree | 67 |
| 8 | two-site | 63 |
| 9 | urn | 54 |
| 10 | quota | 53 |
| 11 | response-adaptive | 41 |
| 12 | expertise-based | 40 |
| 13 | high-powered | 21 |
| 14 | insync | 18 |
| 15 | covariate-adaptive | 16 |
| 16 | supercell | 14 |
| 17 | outcome-adaptive | 13 |
| 18 | 3-l | 12 |
| 19 | dutch-belgian | 12 |
| 20 | cutoff-based | 10 |
| 21 | conglomerate | 8 |
| 22 | cuboid | 8 |
| 23 | effectiveness-implementation | 8 |
| 24 | fluidized-bed | 7 |
| 25 | clinically-integrated | 6 |
| 26 | dionex | 6 |
| 27 | stratified-block | 6 |
| 28 | 'mendelian | 5 |
| 29 | trial-a | 5 |
| 30 | 'myasthenia | 4 |
| 31 | 2108 | 4 |
| 32 | biophase | 4 |
| 33 | malolactic | 4 |
| 34 | multi-disease | 4 |
| 35 | zelen-design | 4 |
| 36 | 10,514 | 3 |
| 37 | 11,648 | 3 |
| 38 | 5-bp | 3 |
| 39 | cross-mouth | 3 |
| 40 | fixed-entry-order | 3 |
| 41 | fluidised-bed | 3 |
| 42 | fp-cavity | 3 |
| 43 | hby | 3 |
| 44 | information-a | 3 |
| 45 | permuted-blocks | 3 |
| 46 | pilot-plant | 3 |
| 47 | pyritum | 3 |
| 48 | split-cluster | 3 |
| 49 | update.two | 3 |
| 50 | 152,850 | 2 |
| 51 | 2day | 2 |
| 52 | 43-item | 2 |
| 53 | antigen-activated | 2 |
| 54 | block-stratified | 2 |
| 55 | block-wise | 2 |
| 56 | cross-disorder | 2 |
| 57 | draeger | 2 |
| 58 | equipoise-stratified | 2 |
| 59 | evidence-2 | 2 |
| 60 | fixed-block | 2 |
| 61 | frugal | 2 |
| 62 | group-clustered | 2 |
| 63 | hexamidine | 2 |
| 64 | hypocompass | 2 |
| 65 | ma.21 | 2 |
| 66 | parallel-cohort | 2 |
| 67 | perspectively | 2 |
| 68 | piccoleto | 2 |
| 69 | pilot-plant-scale | 2 |
| 70 | pre-encounter | 2 |
| 71 | radline | 2 |
| 72 | repeated-batch | 2 |
| 73 | single-eye | 2 |
| 74 | superpopulation | 2 |
| 75 | swiss-one | 2 |
| 76 | thermonuclear | 2 |
| 77 | trial/telmisartan | 2 |
| 78 | visible-light-promoted | 2 |
| 79 | yoking | 2 |
| 80 | 'pitcher | 1 |
| 81 | .current | 1 |
| 82 | 1.823 | 1 |
| 83 | 10,607 | 1 |
| 84 | 10,694 | 1 |
| 85 | 105,791 | 1 |
| 86 | 12,453 | 1 |
| 87 | 121/231 | 1 |
| 88 | 12303 | 1 |
| 89 | 156/254 | 1 |
| 90 | 16-centre | 1 |
| 91 | 16-page | 1 |
| 92 | 1764-bp | 1 |
| 93 | 19-nation | 1 |
| 94 | 2,071 | 1 |
| 95 | 20,548 | 1 |
| 96 | 203,788 | 1 |
| 97 | 21-impacted | 1 |
| 98 | 2178-bp | 1 |
| 99 | 226,141 | 1 |
| 100 | 28,964 | 1 |
| 101 | 3,048 | 1 |
| 102 | 3,775 | 1 |
| 103 | 301-a | 1 |
| 104 | 32.144 | 1 |
| 105 | 37°c/20-h | 1 |
| 106 | 39,605 | 1 |
| 107 | 3d.this | 1 |
| 108 | 4,580 | 1 |
| 109 | 4,688 | 1 |
| 110 | 470-g | 1 |
| 111 | 473,442 | 1 |
| 112 | 4753 | 1 |
| 113 | 52,158 | 1 |
| 114 | 555/1826 | 1 |
| 115 | 557,192 | 1 |
| 116 | 5662 | 1 |
| 117 | 57-week | 1 |
| 118 | 62,605 | 1 |
| 119 | 6680 | 1 |
| 120 | 70,528 | 1 |
| 121 | 73-d | 1 |
| 122 | 74,524 | 1 |
| 123 | 8,130 | 1 |
| 124 | 8,284 | 1 |
| 125 | 85,671 | 1 |
| 126 | 8578 | 1 |
| 127 | 8815 | 1 |
| 128 | 92,817 | 1 |
| 129 | 92/174 | 1 |
| 130 | 96-item | 1 |
| 131 | 975-bp | 1 |
| 132 | ahead—a | 1 |
| 133 | analgesic-overuse | 1 |
| 134 | analyst-masked | 1 |
| 135 | art.three | 1 |
| 136 | b=small | 1 |
| 137 | batch/fed-batch | 1 |
| 138 | better-powered | 1 |
| 139 | big-stick | 1 |
| 140 | capsules.4 | 1 |
| 141 | catheter-dialysis | 1 |
| 142 | chelonian | 1 |
| 143 | child-relevant | 1 |
| 144 | cholangiopathies | 1 |
| 145 | class-clustered | 1 |
| 146 | clip-01 | 1 |
| 147 | cohort-embedded | 1 |
| 148 | collagen-labeled | 1 |
| 149 | computer-program | 1 |
| 150 | controlled-forcing | 1 |
| 151 | covariate-constrained | 1 |
| 152 | cr/lx | 1 |
| 153 | dacarbazine-controlled | 1 |
| 154 | dalteparin-controlled | 1 |
| 155 | data-analyst-blinded | 1 |
| 156 | dental-related | 1 |
| 157 | design-identical | 1 |
| 158 | diseases-b | 1 |
| 159 | electroblot | 1 |
| 160 | english/chinese | 1 |
| 161 | eurofoetus | 1 |
| 162 | evaluation-2 | 1 |
| 163 | evidence-1 | 1 |
| 164 | evidence-the | 1 |
| 165 | ferro-manganese | 1 |
| 166 | fixation.five | 1 |
| 167 | florence-angiojet | 1 |
| 168 | general.this | 1 |
| 169 | harmful-dysfunction | 1 |
| 170 | hgaj | 1 |
| 171 | hypertrophy-a | 1 |
| 172 | information-an | 1 |
| 173 | isar-smart-3 | 1 |
| 174 | isotretinoin-925 | 1 |
| 175 | komplementärmed | 1 |
| 176 | language-stratified | 1 |
| 177 | leftright | 1 |
| 178 | legalizes | 1 |
| 179 | levels.more | 1 |
| 180 | lifelax | 1 |
| 181 | light-polymerizing | 1 |
| 182 | macrophage-to-feces | 1 |
| 183 | match-design | 1 |
| 184 | mds-based | 1 |
| 185 | min.after | 1 |
| 186 | monocentral | 1 |
| 187 | multiple-electrode | 1 |
| 188 | mutation-confirmed | 1 |
| 189 | net-central | 1 |
| 190 | newly-conceived | 1 |
| 191 | non-isobaric | 1 |
| 192 | nondefinitive | 1 |
| 193 | orthopaedics-related | 1 |
| 194 | outcome-focused | 1 |
| 195 | pami-1 | 1 |
| 196 | pci99 | 1 |
| 197 | pharmaceutical-industry-sponsored | 1 |
| 198 | pid-c. | 1 |
| 199 | postoper* | 1 |
| 200 | premeva | 1 |
| 201 | rab11a-knockout | 1 |
| 202 | reasonable-quality | 1 |
| 203 | record1-3 | 1 |
| 204 | red-lit | 1 |
| 205 | relavant | 1 |
| 206 | resultsthree | 1 |
| 207 | retroscope® | 1 |
| 208 | roche-sponsored | 1 |
| 209 | safe-life | 1 |
| 210 | semifactorial | 1 |
| 211 | sinus/leaflet | 1 |
| 212 | software-generated | 1 |
| 213 | stratified-cluster | 1 |
| 214 | superiority-type | 1 |
| 215 | systematmic | 1 |
| 216 | testing-a | 1 |
| 217 | tls.the | 1 |
| 218 | tongŭi | 1 |
| 219 | treatment.sequentially | 1 |
| 220 | trochanter.two | 1 |
| 221 | trp-trp | 1 |
| 222 | ts-mutation | 1 |
| 223 | two-ring | 1 |
| 224 | type-of-age | 1 |
| 225 | unretracted | 1 |
| 226 | waste-fluid | 1 |
| 227 | well-acquired | 1 |
| 228 | within-church | 1 |
| 229 | zelen-type | 1 |
| 1 | 'mendelian | 5 |
| 2 | 'myasthenia | 4 |
| 3 | 'pitcher | 1 |
| 4 | .current | 1 |
| 5 | 1.823 | 1 |
| 6 | 10,514 | 3 |
| 7 | 10,607 | 1 |
| 8 | 10,694 | 1 |
| 9 | 105,791 | 1 |
| 10 | 11,648 | 3 |
| 11 | 12,453 | 1 |
| 12 | 121/231 | 1 |
| 13 | 12303 | 1 |
| 14 | 152,850 | 2 |
| 15 | 156/254 | 1 |
| 16 | 16-centre | 1 |
| 17 | 16-page | 1 |
| 18 | 1764-bp | 1 |
| 19 | 19-nation | 1 |
| 20 | 2,071 | 1 |
| 21 | 20,548 | 1 |
| 22 | 203,788 | 1 |
| 23 | 21-impacted | 1 |
| 24 | 2108 | 4 |
| 25 | 2178-bp | 1 |
| 26 | 226,141 | 1 |
| 27 | 28,964 | 1 |
| 28 | 2day | 2 |
| 29 | 3,048 | 1 |
| 30 | 3,775 | 1 |
| 31 | 3-l | 12 |
| 32 | 301-a | 1 |
| 33 | 32.144 | 1 |
| 34 | 37°c/20-h | 1 |
| 35 | 39,605 | 1 |
| 36 | 3d.this | 1 |
| 37 | 4,580 | 1 |
| 38 | 4,688 | 1 |
| 39 | 43-item | 2 |
| 40 | 470-g | 1 |
| 41 | 473,442 | 1 |
| 42 | 4753 | 1 |
| 43 | 5-bp | 3 |
| 44 | 52,158 | 1 |
| 45 | 555/1826 | 1 |
| 46 | 557,192 | 1 |
| 47 | 5662 | 1 |
| 48 | 57-week | 1 |
| 49 | 62,605 | 1 |
| 50 | 6680 | 1 |
| 51 | 70,528 | 1 |
| 52 | 73-d | 1 |
| 53 | 74,524 | 1 |
| 54 | 8,130 | 1 |
| 55 | 8,284 | 1 |
| 56 | 85,671 | 1 |
| 57 | 8578 | 1 |
| 58 | 8815 | 1 |
| 59 | 92,817 | 1 |
| 60 | 92/174 | 1 |
| 61 | 96-item | 1 |
| 62 | 975-bp | 1 |
| 63 | ahead—a | 1 |
| 64 | analgesic-overuse | 1 |
| 65 | analyst-masked | 1 |
| 66 | antigen-activated | 2 |
| 67 | art.three | 1 |
| 68 | b=small | 1 |
| 69 | batch | 482 |
| 70 | batch/fed-batch | 1 |
| 71 | better-powered | 1 |
| 72 | big-stick | 1 |
| 73 | biophase | 4 |
| 74 | block-stratified | 2 |
| 75 | block-wise | 2 |
| 76 | capsules.4 | 1 |
| 77 | catheter-dialysis | 1 |
| 78 | chelonian | 1 |
| 79 | child-relevant | 1 |
| 80 | cholangiopathies | 1 |
| 81 | class-clustered | 1 |
| 82 | clinically-integrated | 6 |
| 83 | clip-01 | 1 |
| 84 | cluster | 5,144 |
| 85 | cohort-embedded | 1 |
| 86 | coin | 88 |
| 87 | collagen-labeled | 1 |
| 88 | computer-program | 1 |
| 89 | conglomerate | 8 |
| 90 | controlled-forcing | 1 |
| 91 | covariate-adaptive | 16 |
| 92 | covariate-constrained | 1 |
| 93 | cr/lx | 1 |
| 94 | cross-disorder | 2 |
| 95 | cross-mouth | 3 |
| 96 | cuboid | 8 |
| 97 | cutoff-based | 10 |
| 98 | dacarbazine-controlled | 1 |
| 99 | dalteparin-controlled | 1 |
| 100 | data-analyst-blinded | 1 |
| 101 | dental-related | 1 |
| 102 | design-identical | 1 |
| 103 | dionex | 6 |
| 104 | diseases-b | 1 |
| 105 | draeger | 2 |
| 106 | dutch-belgian | 12 |
| 107 | effectiveness-implementation | 8 |
| 108 | electroblot | 1 |
| 109 | english/chinese | 1 |
| 110 | equipoise-stratified | 2 |
| 111 | eurofoetus | 1 |
| 112 | evaluation-2 | 1 |
| 113 | evidence-1 | 1 |
| 114 | evidence-2 | 2 |
| 115 | evidence-the | 1 |
| 116 | expertise-based | 40 |
| 117 | fed-batch | 110 |
| 118 | ferro-manganese | 1 |
| 119 | fixation.five | 1 |
| 120 | fixed-block | 2 |
| 121 | fixed-entry-order | 3 |
| 122 | florence-angiojet | 1 |
| 123 | fluidised-bed | 3 |
| 124 | fluidized-bed | 7 |
| 125 | fp-cavity | 3 |
| 126 | frugal | 2 |
| 127 | general.this | 1 |
| 128 | group-clustered | 2 |
| 129 | harmful-dysfunction | 1 |
| 130 | hby | 3 |
| 131 | hexamidine | 2 |
| 132 | hgaj | 1 |
| 133 | high-powered | 21 |
| 134 | hypertrophy-a | 1 |
| 135 | hypocompass | 2 |
| 136 | information-a | 3 |
| 137 | information-an | 1 |
| 138 | insync | 18 |
| 139 | isar-smart-3 | 1 |
| 140 | isotretinoin-925 | 1 |
| 141 | komplementärmed | 1 |
| 142 | language-stratified | 1 |
| 143 | leftright | 1 |
| 144 | legalizes | 1 |
| 145 | levels.more | 1 |
| 146 | lifelax | 1 |
| 147 | light-polymerizing | 1 |
| 148 | ma.21 | 2 |
| 149 | macrophage-to-feces | 1 |
| 150 | malolactic | 4 |
| 151 | match-design | 1 |
| 152 | mds-based | 1 |
| 153 | mendelian | 95 |
| 154 | min.after | 1 |
| 155 | monocentral | 1 |
| 156 | multi-disease | 4 |
| 157 | multiple-electrode | 1 |
| 158 | mutation-confirmed | 1 |
| 159 | net-central | 1 |
| 160 | newly-conceived | 1 |
| 161 | non-isobaric | 1 |
| 162 | nondefinitive | 1 |
| 163 | orthopaedics-related | 1 |
| 164 | outcome-adaptive | 13 |
| 165 | outcome-focused | 1 |
| 166 | pami-1 | 1 |
| 167 | parallel-cohort | 2 |
| 168 | pci99 | 1 |
| 169 | pedigree | 67 |
| 170 | permuted-blocks | 3 |
| 171 | perspectively | 2 |
| 172 | pharmaceutical-industry-sponsored | 1 |
| 173 | piccoleto | 2 |
| 174 | pid-c. | 1 |
| 175 | pilot-plant | 3 |
| 176 | pilot-plant-scale | 2 |
| 177 | postoper* | 1 |
| 178 | pre-encounter | 2 |
| 179 | premeva | 1 |
| 180 | pyritum | 3 |
| 181 | quasi | 109 |
| 182 | quota | 53 |
| 183 | rab11a-knockout | 1 |
| 184 | radline | 2 |
| 185 | reasonable-quality | 1 |
| 186 | record1-3 | 1 |
| 187 | red-lit | 1 |
| 188 | relavant | 1 |
| 189 | repeated-batch | 2 |
| 190 | response-adaptive | 41 |
| 191 | resultsthree | 1 |
| 192 | retroscope® | 1 |
| 193 | roche-sponsored | 1 |
| 194 | safe-life | 1 |
| 195 | semifactorial | 1 |
| 196 | single-eye | 2 |
| 197 | sinus/leaflet | 1 |
| 198 | software-generated | 1 |
| 199 | split-cluster | 3 |
| 200 | stratified-block | 6 |
| 201 | stratified-cluster | 1 |
| 202 | supercell | 14 |
| 203 | superiority-type | 1 |
| 204 | superpopulation | 2 |
| 205 | swiss-one | 2 |
| 206 | systematmic | 1 |
| 207 | testing-a | 1 |
| 208 | thermonuclear | 2 |
| 209 | tls.the | 1 |
| 210 | tongŭi | 1 |
| 211 | treatment.sequentially | 1 |
| 212 | trial-a | 5 |
| 213 | trial/telmisartan | 2 |
| 214 | trochanter.two | 1 |
| 215 | trp-trp | 1 |
| 216 | ts-mutation | 1 |
| 217 | two-ring | 1 |
| 218 | two-site | 63 |
| 219 | type-of-age | 1 |
| 220 | unretracted | 1 |
| 221 | update.two | 3 |
| 222 | urn | 54 |
| 223 | visible-light-promoted | 2 |
| 224 | waste-fluid | 1 |
| 225 | well-acquired | 1 |
| 226 | within-church | 1 |
| 227 | yoking | 2 |
| 228 | zelen-design | 4 |
| 229 | zelen-type | 1 |
| 1 | postoper* | 1 |
| 2 | pid-c. | 1 |
| 3 | 8,130 | 1 |
| 4 | 152,850 | 2 |
| 5 | 4,580 | 1 |
| 6 | 6680 | 1 |
| 7 | evidence-1 | 1 |
| 8 | pami-1 | 1 |
| 9 | clip-01 | 1 |
| 10 | ma.21 | 2 |
| 11 | 121/231 | 1 |
| 12 | 226,141 | 1 |
| 13 | 2,071 | 1 |
| 14 | 85,671 | 1 |
| 15 | 105,791 | 1 |
| 16 | evidence-2 | 2 |
| 17 | evaluation-2 | 1 |
| 18 | 473,442 | 1 |
| 19 | 5662 | 1 |
| 20 | 557,192 | 1 |
| 21 | record1-3 | 1 |
| 22 | isar-smart-3 | 1 |
| 23 | 12303 | 1 |
| 24 | 1.823 | 1 |
| 25 | 12,453 | 1 |
| 26 | 4753 | 1 |
| 27 | capsules.4 | 1 |
| 28 | 10,514 | 3 |
| 29 | 74,524 | 1 |
| 30 | 32.144 | 1 |
| 31 | 156/254 | 1 |
| 32 | 28,964 | 1 |
| 33 | 92/174 | 1 |
| 34 | 8,284 | 1 |
| 35 | 10,694 | 1 |
| 36 | 62,605 | 1 |
| 37 | 39,605 | 1 |
| 38 | 8815 | 1 |
| 39 | isotretinoin-925 | 1 |
| 40 | 3,775 | 1 |
| 41 | 555/1826 | 1 |
| 42 | 10,607 | 1 |
| 43 | 92,817 | 1 |
| 44 | 2108 | 4 |
| 45 | 70,528 | 1 |
| 46 | 3,048 | 1 |
| 47 | 20,548 | 1 |
| 48 | 11,648 | 3 |
| 49 | 52,158 | 1 |
| 50 | 8578 | 1 |
| 51 | 4,688 | 1 |
| 52 | 203,788 | 1 |
| 53 | pci99 | 1 |
| 54 | 301-a | 1 |
| 55 | testing-a | 1 |
| 56 | trial-a | 5 |
| 57 | information-a | 3 |
| 58 | hypertrophy-a | 1 |
| 59 | 'myasthenia | 4 |
| 60 | quota | 53 |
| 61 | premeva | 1 |
| 62 | ahead—a | 1 |
| 63 | diseases-b | 1 |
| 64 | systematmic | 1 |
| 65 | non-isobaric | 1 |
| 66 | malolactic | 4 |
| 67 | insync | 18 |
| 68 | 73-d | 1 |
| 69 | fluidised-bed | 3 |
| 70 | fluidized-bed | 7 |
| 71 | cohort-embedded | 1 |
| 72 | data-analyst-blinded | 1 |
| 73 | language-stratified | 1 |
| 74 | equipoise-stratified | 2 |
| 75 | block-stratified | 2 |
| 76 | analyst-masked | 1 |
| 77 | collagen-labeled | 1 |
| 78 | dacarbazine-controlled | 1 |
| 79 | dalteparin-controlled | 1 |
| 80 | mutation-confirmed | 1 |
| 81 | komplementärmed | 1 |
| 82 | covariate-constrained | 1 |
| 83 | group-clustered | 2 |
| 84 | class-clustered | 1 |
| 85 | high-powered | 21 |
| 86 | better-powered | 1 |
| 87 | well-acquired | 1 |
| 88 | roche-sponsored | 1 |
| 89 | pharmaceutical-industry-sponsored | 1 |
| 90 | expertise-based | 40 |
| 91 | cutoff-based | 10 |
| 92 | mds-based | 1 |
| 93 | outcome-focused | 1 |
| 94 | dental-related | 1 |
| 95 | orthopaedics-related | 1 |
| 96 | software-generated | 1 |
| 97 | clinically-integrated | 6 |
| 98 | antigen-activated | 2 |
| 99 | 21-impacted | 1 |
| 100 | unretracted | 1 |
| 101 | visible-light-promoted | 2 |
| 102 | newly-conceived | 1 |
| 103 | cuboid | 8 |
| 104 | waste-fluid | 1 |
| 105 | multiple-electrode | 1 |
| 106 | pedigree | 67 |
| 107 | art.three | 1 |
| 108 | resultsthree | 1 |
| 109 | safe-life | 1 |
| 110 | type-of-age | 1 |
| 111 | 16-page | 1 |
| 112 | evidence-the | 1 |
| 113 | tls.the | 1 |
| 114 | pilot-plant-scale | 2 |
| 115 | hexamidine | 2 |
| 116 | radline | 2 |
| 117 | swiss-one | 2 |
| 118 | zelen-type | 1 |
| 119 | superiority-type | 1 |
| 120 | levels.more | 1 |
| 121 | 16-centre | 1 |
| 122 | multi-disease | 4 |
| 123 | biophase | 4 |
| 124 | ferro-manganese | 1 |
| 125 | english/chinese | 1 |
| 126 | block-wise | 2 |
| 127 | analgesic-overuse | 1 |
| 128 | conglomerate | 8 |
| 129 | two-site | 63 |
| 130 | fixation.five | 1 |
| 131 | nondefinitive | 1 |
| 132 | outcome-adaptive | 13 |
| 133 | response-adaptive | 41 |
| 134 | covariate-adaptive | 16 |
| 135 | single-eye | 2 |
| 136 | 470-g | 1 |
| 137 | controlled-forcing | 1 |
| 138 | yoking | 2 |
| 139 | two-ring | 1 |
| 140 | light-polymerizing | 1 |
| 141 | 37°c/20-h | 1 |
| 142 | within-church | 1 |
| 143 | batch | 482 |
| 144 | fed-batch | 110 |
| 145 | batch/fed-batch | 1 |
| 146 | repeated-batch | 2 |
| 147 | cross-mouth | 3 |
| 148 | quasi | 109 |
| 149 | tongŭi | 1 |
| 150 | hgaj | 1 |
| 151 | big-stick | 1 |
| 152 | stratified-block | 6 |
| 153 | fixed-block | 2 |
| 154 | 57-week | 1 |
| 155 | 3-l | 12 |
| 156 | design-identical | 1 |
| 157 | frugal | 2 |
| 158 | semifactorial | 1 |
| 159 | net-central | 1 |
| 160 | monocentral | 1 |
| 161 | b=small | 1 |
| 162 | supercell | 14 |
| 163 | computer-program | 1 |
| 164 | 43-item | 2 |
| 165 | 96-item | 1 |
| 166 | pyritum | 3 |
| 167 | information-an | 1 |
| 168 | dutch-belgian | 12 |
| 169 | mendelian | 95 |
| 170 | 'mendelian | 5 |
| 171 | chelonian | 1 |
| 172 | trial/telmisartan | 2 |
| 173 | match-design | 1 |
| 174 | zelen-design | 4 |
| 175 | coin | 88 |
| 176 | superpopulation | 2 |
| 177 | 19-nation | 1 |
| 178 | effectiveness-implementation | 8 |
| 179 | ts-mutation | 1 |
| 180 | harmful-dysfunction | 1 |
| 181 | urn | 54 |
| 182 | piccoleto | 2 |
| 183 | update.two | 3 |
| 184 | trochanter.two | 1 |
| 185 | 1764-bp | 1 |
| 186 | 5-bp | 3 |
| 187 | 975-bp | 1 |
| 188 | 2178-bp | 1 |
| 189 | trp-trp | 1 |
| 190 | thermonuclear | 2 |
| 191 | fixed-entry-order | 3 |
| 192 | cross-disorder | 2 |
| 193 | draeger | 2 |
| 194 | 'pitcher | 1 |
| 195 | min.after | 1 |
| 196 | pre-encounter | 2 |
| 197 | cluster | 5,144 |
| 198 | stratified-cluster | 1 |
| 199 | split-cluster | 3 |
| 200 | macrophage-to-feces | 1 |
| 201 | cholangiopathies | 1 |
| 202 | legalizes | 1 |
| 203 | 3d.this | 1 |
| 204 | general.this | 1 |
| 205 | catheter-dialysis | 1 |
| 206 | permuted-blocks | 3 |
| 207 | hypocompass | 2 |
| 208 | eurofoetus | 1 |
| 209 | florence-angiojet | 1 |
| 210 | sinus/leaflet | 1 |
| 211 | leftright | 1 |
| 212 | red-lit | 1 |
| 213 | pilot-plant | 3 |
| 214 | relavant | 1 |
| 215 | child-relevant | 1 |
| 216 | .current | 1 |
| 217 | electroblot | 1 |
| 218 | parallel-cohort | 2 |
| 219 | rab11a-knockout | 1 |
| 220 | lifelax | 1 |
| 221 | dionex | 6 |
| 222 | cr/lx | 1 |
| 223 | 2day | 2 |
| 224 | hby | 3 |
| 225 | perspectively | 2 |
| 226 | treatment.sequentially | 1 |
| 227 | reasonable-quality | 1 |
| 228 | fp-cavity | 3 |
| 229 | retroscope® | 1 |